Evidence map›Paper›PMID 31346173›Full record

ArticleNature communications2019

Author Correction: A practical guide for mutational signature analysis in hematological malignancies.

Francesco Maura, Andrea Degasperi, Ferran Nadeu, Daniel Leongamornlert, Helen Davies, Luiza Moore, Romina Royo, Bachisio Ziccheddu, Xose S Puente, Herve Avet-Loiseau and 5 more

Open access · goldAbstract readPublished Erratum
In one paragraph

Article in Nature communications, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.1field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 10 institutions in 5 countries.

Francesco MauraMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, 10065 NY, USA. mauraf@mskcc.org.
Andrea DegasperiCancer, Ageing, and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.ORCID http://orcid.org/0000-0001-6879-0596
Ferran NadeuPatologia Molecular de Neoplàsies Limfoides, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2910-9440
Daniel LeongamornlertCancer, Ageing, and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Helen DaviesCancer, Ageing, and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Luiza MooreCancer, Ageing, and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.ORCID http://orcid.org/0000-0001-5315-516X
Romina RoyoBarcelona Supercomputing Center (BSC), Joint BSC-CRG-IRB Research Program in Computational Biology, 08036, Barcelona, Spain.
Bachisio ZicchedduDepartment of Clinical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, 20133, Italy.
Xose S PuenteUnitat Hematopatologia, Hospital Clínic of Barcelona, Universitat de Barcelona, 08036, Barcelona, Spain.ORCID http://orcid.org/0000-0001-9525-1483
Herve Avet-LoiseauIUC-Oncopole, and CRCT INSERM U1037, 31100, Toulouse, France.
Peter J CampbellCancer, Ageing, and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Serena Nik-ZainalCancer, Ageing, and Somatic Mutation Programme, Wellcome Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK.
Elias CampoPatologia Molecular de Neoplàsies Limfoides, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), 08036, Barcelona, Spain.
Nikhil MunshiJerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, 02215, MA, USA.
Niccolò BolliDepartment of Oncology and Hemato-Oncology, University of Milan, Via Festa del Perdono 7, Milan, 20122, Italy. niccolo.bolli@unimi.it.
University of Cambridge · GBWellcome Sanger Institute · GBBarcelona Supercomputing Center · ESCentro de Investigación Biomédica en Red de Cáncer · ESFondazione IRCCS Istituto Nazionale dei Tumori · ITHarvard University · USInserm · FRMemorial Sloan Kettering Cancer Center · USUniversidad de Oviedo · ESUniversity of Milan · IT

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Genomic Instability and Evolution in MyelomaP01CA155258 · NCI · DANA-FARBER CANCER INST · PI Nikhil C. Munshi · 2011 to 2026
$32.5M
MOLECULAR MANIPULATION TO ENHANCE ANTI-MYELOMA RESPONSEI01BX001584 · VA · VA BOSTON HEALTH CARE SYSTEM · PI MUNSHI, NIKHIL C. · 2013 to 2025
–
BLRD VA I01 BX001584NCI NIH HHS P01 CA155258NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.

Identifiers

PMID31346173
PMCPMC6658484
OpenAlexW2962888084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.